Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $24,939 | 1,231 | 93.3% |
| Consulting Fee | $1,625 | 1 | 6.1% |
| Education | $172.14 | 12 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $3,957 | 86 | $0 (2024) |
| ABBVIE INC. | $2,400 | 118 | $0 (2024) |
| ViiV Healthcare Company | $2,130 | 114 | $0 (2024) |
| Amgen Inc. | $1,601 | 83 | $0 (2024) |
| Gilead Sciences, Inc. | $1,551 | 79 | $0 (2024) |
| Novo Nordisk Inc | $1,497 | 83 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,052 | 26 | $0 (2022) |
| PFIZER INC. | $1,040 | 68 | $0 (2022) |
| Bausch Health US, LLC | $1,022 | 67 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $824.93 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,494 | 158 | ABBVIE INC. ($507.37) |
| 2023 | $3,681 | 175 | ABBVIE INC. ($607.99) |
| 2022 | $3,299 | 161 | Janssen Pharmaceuticals, Inc ($481.85) |
| 2021 | $4,924 | 160 | Janssen Pharmaceuticals, Inc ($2,181) |
| 2020 | $2,950 | 143 | ViiV Healthcare Company ($382.44) |
| 2019 | $3,346 | 161 | Novo Nordisk Inc ($429.80) |
| 2018 | $2,641 | 157 | SANOFI-AVENTIS U.S. LLC ($287.12) |
| 2017 | $2,402 | 129 | SANOFI-AVENTIS U.S. LLC ($450.25) |
All Payment Transactions
1,244 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: PSYCHIATRY | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.78 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: RESPIRATORY | ||||||
| 12/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: PSYCHIATRY | ||||||
| 11/25/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.77 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $8.51 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.62 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.19 | General |
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.30 | General |
| 10/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $9.51 | General |
| Category: Neurology | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.42 | General |
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $2.81 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Insomnia | ||||||
| 10/15/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $7.23 | General |
| Category: Inflammation | ||||||
| 10/14/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $23.09 | General |
| Category: Infectious Disease | ||||||
| 10/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.61 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $9.78 | General |
| Category: Neurology | ||||||
| 10/08/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $39.69 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 6,082 | 118,248 | $2.3M | $797,793 |
| 2022 | 57 | 6,471 | 102,784 | $2.8M | $993,512 |
| 2021 | 47 | 5,419 | 85,978 | $1.9M | $687,461 |
| 2020 | 46 | 5,015 | 73,414 | $9.0M | $465,656 |
All Medicare Procedures & Services
202 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 499 | 1,874 | $431,020 | $199,544 | 46.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 470 | 746 | $205,150 | $108,708 | 53.0% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2023 | 461 | 2,076 | $311,102 | $103,839 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 431 | 1,166 | $219,208 | $85,337 | 38.9% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 13 | 6,532 | $130,640 | $61,441 | 47.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 474 | 1,499 | $89,940 | $32,902 | 36.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,740 | $45,240 | $32,031 | 70.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 271 | 2,458 | $145,232 | $29,178 | 20.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 240 | 249 | $24,901 | $17,853 | 71.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 512 | 2,038 | $109,626 | $17,259 | 15.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 235 | 385 | $153,601 | $13,214 | 8.6% |
| 71045 | X-ray of chest, 1 view | Office | 2023 | 222 | 478 | $76,480 | $10,814 | 14.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 246 | 255 | $10,795 | $8,516 | 78.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 72 | 121 | $17,063 | $7,252 | 42.5% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2023 | 38 | 38 | $17,100 | $6,137 | 35.9% |
| J1460 | Injection, gamma globulin, intramuscular, 1 cc | Office | 2023 | 27 | 156 | $8,092 | $5,885 | 72.7% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2023 | 330 | 330 | $8,091 | $5,838 | 72.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 52 | $13,520 | $5,184 | 38.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 119 | 282 | $10,434 | $4,623 | 44.3% |
| J0561 | Injection, penicillin g benzathine, 100,000 units | Office | 2023 | 19 | 276 | $7,512 | $4,242 | 56.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 39 | 82 | $5,400 | $3,940 | 73.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 64 | $16,960 | $3,767 | 22.2% |
| J3121 | Injection, testosterone enanthate, 1 mg | Office | 2023 | 42 | 90,240 | $54,144 | $3,086 | 5.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 18 | $6,170 | $2,615 | 42.4% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 54 | 64 | $4,480 | $2,466 | 55.0% |
About Dr. Stephen Henry, M.D
Dr. Stephen Henry, M.D is a Geriatric Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811925183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Henry, M.D has received a total of $26,736 in payments from pharmaceutical and medical device companies, with $3,494 received in 2024. These payments were reported across 1,244 transactions from 88 companies. The most common payment nature is "Food and Beverage" ($24,939).
As a Medicare-enrolled provider, Henry has provided services to 22,987 Medicare beneficiaries, totaling 380,424 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 202 distinct procedure/service records.
Practice Information
- Specialty Geriatric Medicine
- Location Pasadena, CA
- Active Since 06/28/2006
- Last Updated 05/18/2011
- Taxonomy Code 207RG0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811925183
Products in Payments
- SPRAVATO (Drug) $3,102
- DOVATO (Drug) $1,336
- PRALUENT (Drug) $1,039
- APLENZIN (Drug) $1,004
- VRAYLAR (Drug) $985.53
- ELIQUIS (Drug) $892.44
- UBRELVY (Drug) $861.22
- REXULTI (Drug) $788.82
- Saxenda (Drug) $739.83
- XARELTO (Drug) $682.34
- Otezla (Drug) $626.04
- Repatha (Biological) $522.49
- Trintellix (Drug) $412.49
- ENTRESTO (Drug) $388.80
- TRELEGY ELLIPTA (Drug) $334.88
- TRIUMEQ (Drug) $308.45
- NEXLETOL (Drug) $298.63
- Ozempic (Drug) $294.46
- XIFAXAN (Drug) $290.70
- JARDIANCE (Drug) $272.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Medicine Doctors in Pasadena
Norman Chien, Md, MD
Geriatric Medicine — Payments: $5,758
Dr. Peter Liepmann, Md, MD
Geriatric Medicine — Payments: $1,930
Steven Doan, M.d, M.D
Geriatric Medicine — Payments: $1,543
Dr. Arbis Rojas, Md, MD
Geriatric Medicine — Payments: $539.49
Dr. Jennifer Li, Md, MD
Geriatric Medicine — Payments: $17.38
Dr. Louise Nocas, M.d, M.D
Geriatric Medicine